Open session of the standing technical committee of the EUFMD- 2004

Progress with FMD Virus detection proficiency panel At the closed meeting of the EUFMD Research Group in Gerzensee, it was agreed that the WRL would prepare a proficiency panel for virus detection tests. This panel would be distributed to a small number of laboratories as a trial and if satisfactory would then be issued more widely. The panel, comprising 20 epithelial samples has been assembled and tested blind at the WRL with good results. It is being distributed to laboratories in Brescia, Lelystad, Riems and Brussels. Letters of undertaking have been requested from the participating laboratories to enable the infectious virus materials to be exported. Some samples have now been sent out, whilst some letters of undertaking are still awaited.

Open session of the standing technical committee of the EUFMD- 2004

Articles inside

Appendix 82

Appendix 77

Appendix 78

Appendix 79

Appendix 81

Appendix 80

Appendix 76

Appendix 75

Appendix 64

Appendix 72

Appendix 73

Appendix 65

Appendix 67

Appendix 63

Appendix 62

Appendix 54

Appendix 61

Appendix 55

Appendix 59

Appendix 60

Appendix 56

Appendix 42

Appendix 52

Appendix 50

Appendix 46

Appendix 37

Appendix 38

Appendix 41

Appendix 40

Appendix 36

Appendix 35

Appendix 34

Appendix 28

Appendix 31

Appendix 29

Appendix 33

Appendix 27

Appendix 26

Appendix 25

Appendix 23

Appendix 22

Appendix 15

Appendix 16

Appendix 20 EMEA paper extract - Recommendations for tests for induction of antibodies to NSP antigens by FMD vaccines

Appendix 19

Appendix 14

Appendix 13

Appendix 5

Appendix 12

Appendix 3

Appendix 4

Appendix 8

Appendix 2

Open Session

Closed Session

Item 11 – Persistent and subclinical infections – diagnostic and surveillance issues

Item 15 – Managing the decision-making process in control of FMD and in the priority setting of research and development

Item 14 – Regulatory compliance

Item 10 – International issues

Item 9 – Novel vaccines

Item 7 – Optimisation of conventional vaccines

Item 4 – Managing diagnostic demands

Item 8 – Regulatory issues affecting FMD vacine selection and use

Item 3 – Transmission and its control

3.4.2 Post-vaccination serosurveillance (PVS) for presence of FMD infected animals

Item 1 – Recent findings in molecular epidemiology of FMDV

Item 2 – Surveillance: for what purpose and how much is enough?

4.2 Collection of sera/specimens for validation of DIVA tests for detection of animals received from SAT virus infection